FDA Approves IGALMI For At-Home Acute Treatment For Agitation Associated With Schizophrenia, Schizoaffective Disorder, Or Bipolar I Or II Disorder in Adults
Teva Pharmaceutical Industries (TEVA) Holds First R&D Day With New Pipeline Milestones
Piper Sandler Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $56
Teva Pharmaceutical Industries (TEVA) Earnings Put Its Turnaround Valuation Back In Focus
Teva Pharmaceutical Industries Targets Up to $7 Billion in Innovative Drug Revenue by 2030
Teva Outlines Aggressive R&D Strategy with $7 Billion in Innovative Medicine Revenue by 2030
Teva Shares Innovative Pipeline Updates and Unveils Path to Future Growth at R&D Day, Targeting $6–7 Billion in Innovative Medicines Revenue by 2030
Teva Pharma Unveils Long-Term Growth Strategy, Targets $6B-$7B In Innovative Medicines Revenue By 2030
Teva's 3 Key Branded Drugs Grew Sales 33% Last Quarter. Is This Turnaround Stock a Buy Right Now?
Teva Pharmaceutical (NYSE:TEVA) Sets Up for Breakout With 10/10 Technical Strength
Teva Pharmaceutical Industries Ltd (TEVA) Q3 2026 Earnings Call Highlights: Innovative ...
Leerink Partners Maintains Outperform on Teva Pharmaceutical Indus, Raises Price Target to $52
Teva Pharmaceutical Industries Limited’s (TEVA) Innovative Brands Drive Stronger Growth
TD Cowen Maintains Buy on Teva Pharmaceutical Indus, Raises Price Target to $57
What Teva Pharmaceutical Industries (TEVA) Said on Its Q3 Earnings Call
HC Wainwright & Co. Maintains Buy on Teva Pharmaceutical Indus, Raises Price Target to $54
Teva CEO Explains Why Drugmaker Is Growing Despite Sales Slump
Teva (TEVA) Q3 2026 Earnings Call Transcript
How Investors Are Reacting To Teva Pharmaceutical Industries (TEVA) Earnings Beat
Why Is Teva (TEVA) Dropping A Drug Trial While Raising Its Outlook?
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.